Capecitabine for Salvage Treatment of Patients With Heavily Pretreated Human Papillomavirus–Associated Oropharynx Cancer With Distant Metastases
- 1 November 2023
- journal article
- research article
- Published by Harborside Press, LLC in Journal of the Advanced Practitioner in Oncology
- Vol. 14 (7) , 571-575
Abstract
Patients with metastatic human papillomavirus-associated oropharyngeal cancer (HPV-OPC) have a median overall survival exceeding 2 years and are often candidates for multiple lines of palliative therapy. With the approval of immunotherapy as first-line treatment, salvage therapeutic options are limited. We describe our experience using capecitabine as salvage therapy for patients with recurrent or metastatic (R/M) HPV-OPC. We performed a retrospective study of patients with R/M HPV-OPC with distant metastatic disease. Eligible patients were identified from a medical oncology clinical database. Demographic and clinical data were abstracted from the medical record. Survival probabilities were estimated with the Kaplan-Meier method. 10 patients were identified. Sites of metastatic disease included lung, liver, mediastinal lymph nodes, bone, abdominal lymph nodes, and soft tissue. Most patients received capecitabine as fourth-line treatment. The median duration from start of capecitabine therapy until death was 10.5 months. Best treatment response was as follows: partial responses (PR) were seen in 4 of 10 (40%), stable disease (SD) in 3 of 10 (30%), and progressive disease (PD) in 2 of 10 (20%). The clinical benefit rate (CR + PR + SD) was 70%. Reasons for discontinuation included disease progression (n = 8) and side effects (n = 2). One patient notably had prolonged benefit from capecitabine and continued to be on treatment for 34 months total. Capecitabine is a potential salvage treatment for heavily pretreated patients with R/M HPV-OPC, with some patients experiencing prolonged response. Clinical or molecular predictors of response would be helpful to identify patients likely to benefit; a larger prospective study would be useful to confirm efficacy in this patient population.Keywords
This publication has 9 references indexed in Scilit:
- Cancer statistics, 2023CA: A Cancer Journal for Clinicians, 2023
- Oral and laryngeal HPV infection: Incidence, prevalence and risk factors, with special regard to concurrent infection in head, neck and genitalsVaccine, 2021
- An analysis of distant metastasis cases from HPV-associated oropharyngeal squamous cell carcinomaJournal of Cranio-Maxillofacial Surgery, 2021
- Unique Patterns of Distant Metastases in HPV-Positive Head and Neck CancerOncology, 2019
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Human Papillomavirus–Associated Oropharyngeal Cancer: Review of Current Evidence and ManagementCurrent Oncology, 2019
- Trends in Human Papillomavirus–Associated Cancers — United States, 1999–2015MMWR. Morbidity and Mortality Weekly Report, 2018
- Cytotoxicity and genotoxicity of capecitabine in head and neck cancer and normal cellsMolecular Biology Reports, 2010
- Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatmentBritish Journal of Cancer, 2010